Protein Degradation, Metabolic
AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront
AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment
Takeda Ventures into Molecular Glue Degraders with Degron Collaboration
Takeda, Degron, molecular glue degraders, pharmaceutical collaboration, targeted protein degradation, drug discovery.